Serum Institute Of India Seeks Permission To Start Clinical Trials Of A New COVID-19 Vaccine, Covavax

The Serum Institute of India has sent out an application to begin clinical trials in the country in the next few days for a new COVID-19 vaccine. Have a look at all the details here.

Serum Institute of India, Pune, has sought permission to start the clinical trials of another vaccine, Covavax, which has been originally developed in by Novavax in America. An application has been sent to the Drugs Controller General of India and the application is in the review process while Serum Institute has been asked to submit the revised protocols for this new vaccine. Novavax is expected to be effective against the new strain of Coronavirus and also claims to have an efficacy of 89.3 per cent. India has currently been manufacturing the Covisheild vaccine which has been developed by Oxford University. The vaccination drive is currently in progress and the health ministry has been requesting the front line workers to come forward and take the dose for a safer future.

Here is a look at the ZEE5 video with details related to the new vaccine and its clinical trial status:

The Serum Institute of India recently sent out an application to DCGI, in order to begin clinical trials of a new vaccine named Novavax. This new vaccine has been developed in America and has been showing promising results in different parts of the world. According to the video posted above, Drugs Controller General of India has been reviewing the application and has also asked the institute to send a few other details about the upcoming trial round.

The CEO of Serum Institute of India recently took to Twitter to announce the process that lies ahead and how they have been approaching the plan. In the tweet, Adar Poonawalla wrote that their partnership with Novavax has fetched excellent results in terms of efficacy. He stated that they have already applied to start the trials in India and have been waiting for official permission. If the process aligns according to their schedule, they have been planning to launch Covovax by June 2021.

Read COVID-19 Vaccine Update: Germany Challenges Efficacy Report of AstraZeneca’s Coronavirus Vaccine

Currently, India has been manufacturing and distributing Covisheild, which has been developed by AstraZeneca. The vaccination drive is already in progress and the government has been trying to provide the frontline workers with the vaccine as soon as possible.

Also read COVID-19 vaccine development: Only 3 vaccine candidates in phase III across world

Watch more informative content only on ZEE5.

Related Topics

Related News

More Loader